As momentum builds on Capitol Hill for comprehensive Pharmacy Benefit Manager (PBM) reform—with parallel legislative and regulatory initiatives gaining traction right here in Florida—employers and plan sponsors are being forced to re-examine how their healthcare dollars are spent. For years, the conventional wisdom among corporate human resources departments and self-insured employers has been straightforward: push for stricter rebate transparency, outlaw predatory spread pricing, clean up contract disclosures, and watch prescription drug costs drop.
However, industry experts and healthcare analysts are issuing a stark warning. Employers who expect new legislative mandates and regulatory transparency rules to automatically translate into lower prescription drug costs are taking too narrow a view of a deeply complex ecosystem.
The financial models utilized by dominant PBMs are remarkably adaptable. When regulatory pressure squeezes traditional revenue streams—such as manufacturer rebates or administrative fees—vertically integrated PBMs have historically shifted where and how revenue is captured across their vast corporate networks, rather than passing savings down to the employers funding the plans.
To unpack this dynamic, stakeholders must look beyond standard administrative charges and rebate guarantees. They must examine the entire architecture of modern pharmacy benefits, including specialty pharmacies, group purchasing organizations (GPOs), rebate aggregators, and mail-order subsidiaries. Ultimately, the success of any PBM reform should not be measured merely by how transparent a contract looks on paper, but by a single, critical metric: whether an employer’s total net pharmacy spend actually declines while maintaining employee access to essential medications.
Detailed Chronology of Regulatory and Legislative Action
The push to rein in PBM practices has evolved from a niche policy debate into a top-tier national priority. Understanding how the current regulatory and legislative landscape took shape requires looking back at a series of pivotal milestones involving federal agencies, antitrust investigations, and proposed labor rules.
1. The FTC’s Expanding Oversight and Vertical Integration Concerns
For decades, PBMs operated largely out of the public eye, functioning as obscure middlemen negotiating drug prices between manufacturers, health plans, and pharmacies. That anonymity began to fade as the Federal Trade Commission (FTC) initiated sweeping inquiries into the industry’s business practices.
The FTC documented an unprecedented level of vertical integration within the PBM sector. The largest PBMs evolved from simple claims-processing middle-men into massive conglomerates that simultaneously own health insurance companies, specialty pharmacies, mail-order facilities, and offshore rebate-aggregation operations. This web of ownership effectively allowed a single corporate entity to sit on multiple sides of a single pharmaceutical transaction—buying, selling, dispensing, and setting prices for drugs.
2. The 2024–2025 Staff Reports on Specialty Generics
Subsequent staff reports published by the FTC pulled back the curtain on how lucrative this vertical integration had become. Researchers analyzed specific specialty generic drugs from 2017 through 2022 and uncovered staggering financial gains. According to the data, the affiliated pharmacies of the three largest PBMs generated more than $7.3 billion in dispensing revenue above estimated acquisition costs on the studied drugs alone.
Furthermore, the FTC’s data revealed that by 2023, pharmacies affiliated with the three largest PBMs had captured an overwhelming 68% of specialty-drug dispensing revenue, a dramatic jump from 54% in 2016. This concentration of dispensing power inside the same corporate family as the PBM created unavoidable conflicts of interest, enabling major PBMs to systematically reimburse their own affiliated pharmacies at higher rates than unaffiliated, independent pharmacies for the exact same medications.
3. The July 2026 FTC Settlements
Regulatory enforcement reached a major turning point in July 2026 when the FTC announced a landmark settlement with CVS Health’s Caremark Rx and its affiliated rebate aggregator, Zinc Health Services. The settlement incorporated targeted measures designed to increase transparency surrounding rebate negotiations and alter specific, historically opaque PBM compensation practices. While heralded by consumer advocates as a step in the right direction, industry insiders immediately cautioned that corporate legal teams would find new ways to structure financial flows.
4. The Department of Labor’s 2026 PBM Disclosure Proposals
Recognizing that federal health agencies and antitrust regulators needed stronger backing in the employer-sponsored plan market, the U.S. Department of Labor (DOL) introduced a sweeping PBM disclosure proposal. Set against the backdrop of the Employee Retirement Income Security Act (ERISA), the 2026 DOL proposal aims to grant employers and plan fiduciaries unprecedented visibility into direct and indirect compensation received by PBMs and their vast network of corporate affiliates.
The proposal establishes that plan sponsors have a fiduciary duty to understand the complete economic framework of their pharmacy benefits. Under the proposed rules, PBMs would be legally required to disclose various payments harvested from drug manufacturers, retail pharmacies, GPOs, and offshore entities—and importantly, give plan fiduciaries the explicit right to audit those disclosures.
Supporting Context & Metrics: The Anatomy of Hidden Revenue
To understand why traditional PBM reform often falls short, one must examine the mechanics of how revenue flows through a modern healthcare supply chain. When an employer contracts with a PBM, the contract typically highlights easily digestible metrics: administrative fees per member per month, guaranteed minimum rebate percentages, and aggressive generic discount rates.
However, these surface-level figures mask a complex maze of internal economics.
The Specialty Pharmacy Monopoly
Specialty medications—used to treat complex, chronic, and rare conditions such as cancer, rheumatoid arthritis, and multiple sclerosis—represent the fastest-growing segment of national healthcare expenditures. They often account for 50% or more of an employer’s total pharmacy benefit spend, despite being utilized by only 1% to 2% of the plan’s membership.
Because specialty drugs command astronomical price tags, they are the primary vehicle for PBM revenue generation. When a PBM mandates that patients utilize its in-house specialty pharmacy, the financial transaction stays entirely within the corporate family.
As Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx—a procurement management solution specializing in high-cost prescription drugs—points out, this structural setup defeats the purpose of conventional cost containment.
“When your PBM controls the dispensing and that’s where most of the revenue comes from, that’s a problem,” Pruitt observes.
By manipulating the spread between what the manufacturer charges, what the PBM’s internal specialty pharmacy is reimbursed, and what the employer plan is billed, the integrated entity captures massive margins that never appear on standard utilization reports.
The Shell Game of Rebate Aggregators and GPOs
Rebate reform has long been the primary battleground for lawmakers. Lawmakers and plan sponsors have demanded that 100% of manufacturer rebates be passed back to employers. While many contracts now claim to pass back "100% of rebates," PBMs have adapted by shifting financial incentives into parallel corporate entities.
Group Purchasing Organizations (GPOs) and rebate aggregators—frequently established by PBMs in foreign jurisdictions or operating as opaque subsidiaries—negotiate administrative fees, data-use fees, and price-concession fees directly with drug manufacturers. Because these fees are legally distinct from traditional "rebates," they are often excluded from standard pass-through accounting guarantees. Consequently, millions of dollars in manufacturer payments continue to flow into the PBM ecosystem under alternative nomenclature, leaving employers footing the bill.
Official Statements and Expert Perspectives
As state-level reforms gain momentum—particularly in states like Florida, where lawmakers are weighing independent PBM oversight legislation—industry experts are sounding the alarm against regulatory complacency.
Paul Pruitt emphasizes that while regulatory intervention and increased transparency are necessary precursors to reform, they must never be mistaken for a complete solution.
“Changing one PBM revenue stream does not automatically translate into lower costs for employers,” Pruitt explains. “The financial model can adjust, so plan sponsors need transparency across the entire arrangement to understand whether reform is producing real savings.”
According to Pruitt, corporate legal and financial teams are adept at regulatory compliance; if a law forces them to surrender revenue in one column of a ledger, they will simply reclassify or re-route those dollars through another subsidiary.
Furthermore, Pruitt warns that regulatory compliance should be treated strictly as the starting point of an audit, rather than proof that total pharmacy economics have been optimized.
“A PBM contract can disclose administrative charges, rebate guarantees, and discount terms while offering limited insight into revenue generated elsewhere within a vertically integrated organization,” Pruitt notes.
When evaluating whether an agreement is genuinely serving the best interests of a self-insured company, plan fiduciaries must look past boilerplate compliance documents and demand full visibility into the totality of the transaction. For Pruitt, the ultimate litmus test of any reform effort is deceptively simple: What happens to the employer’s total net pharmacy spend, and does the plan maintain seamless, barrier-free access for employees needing their medications?
Future Outlook: What Plan Sponsors and Employers Must Do Now
As federal and state regulators press forward with rules like the Department of Labor’s PBM disclosure framework and FTC antitrust enforcement actions, employers can no longer afford a passive approach to pharmacy benefit management. Relying on traditional PBM brokers or accepting standard contract renewals without independent validation is a financial liability.
To safeguard their organizations and employees from hidden cost-shifting, plan sponsors and fiduciaries should adopt a proactive, multi-step strategy:
1. Demand Total-Cost Transparency
Employers must push beyond surface-level contract terms (such as nominal administrative fees and headline rebate guarantees). Contracts must be negotiated to mandate full disclosure of all direct and indirect compensation—including revenue generated by affiliated specialty pharmacies, mail-order facilities, GPOs, and rebate aggregators.
2. Exercise Fiduciary Audit Rights
With the Department of Labor emphasizing fiduciary responsibility under ERISA, plan sponsors have both the right and the duty to audit their PBMs. Engaging independent, third-party procurement and auditing specialists—such as SHARx and similar independent advisory firms—allows employers to peer inside the "black box" of PBM pricing and verify whether promised savings are real or merely cosmetic.
3. Decouple Services Where Necessary
Self-insured employers should explore unbundled pharmacy benefit models. By separating claims processing from specialty drug management, rebate negotiation, and formulary design, employers can eliminate the perverse incentives inherent in vertically integrated PBM conglomerates.
4. Monitor State and Federal Legislative Shifts
As legislative sessions unfold in Florida and across the country, employer coalitions must actively support legislation that strengthens oversight, bans spread pricing, outlaws anticompetitive patient-steering practices, and mandates true fiduciary accountability for PBMs.
Conclusion
The accelerating wave of PBM reform represents a historic opportunity to bring accountability to a notoriously opaque sector of the American healthcare economy. However, as industry experts caution, transparency is merely a tool, not a guarantee.
For employers hoping to rein in runaway healthcare expenditures, the road ahead requires relentless vigilance, comprehensive data audits, and a refusal to let financial engineering mask the true cost of care. Only by looking past traditional metrics and evaluating the total net economic impact can plan sponsors protect their bottom lines and ensure their workforce retains affordable access to life-saving medications.
0 Comments